Pneumococcal Vaccination in Patients With Anti-TNF Alpha Therapy

Study Overview
=================
Brief Summary
-----------------
As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital. The aim of this study is to assess the status of pneumococcal vaccination in patients at the NOVO hospital - Pontoise site, who have received anti-TNF alpha therapy.

Detailed Description
-----------------
Immunosuppressed patients are at risk of infections, sometimes severe with life-threatening consequences. Some of these are vaccine-preventable, notably pneumococcal infections. Specific vaccination recommendations have been published since 2012 by the French High Council for Public Health. However, vaccine coverage is below the desired immunisation objectives for immunosuppressed patients. As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital, in order to propose, if necessary, measures, in particular a specialised consultation, with the aim of improving the vaccination coverage of this population at risk The aim of this study is to assess the status of pneumococcal vaccination in patients who have received anti-TNF alpha therapy.

Official Title
-----------------
Pneumococcal Vaccination in Patients With Anti-TNF Alpha Therapy: Status Report on the NOVO Hospital - Pontoise Site

Conditions
-----------------
Pneumococcal Vaccine

Intervention / Treatment
-----------------
* Other: Pneumococcal vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria : Patients treated with anti-TNF alpha between 2020 and 2022 at the NOVO Hospital - Pontoise site Exclusion Criteria : Patients with an indication for pneumococcal vaccination who have received a full vaccination regimen prior to the decision to start anti-TNF alpha

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pneumococcal vaccine<br>Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy | Other: Pneumococcal vaccine<br>* Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the prescription of a pneumococcal vaccination (Conjugated or Unconjugated Pneumococcal Vaccine) by doctors practising at the NOVO Hospital - Pontoise site, in patients receiving anti-TNF alpha treatment | Presence or absence of a prescription or completion of a complete pneumococcal vaccination (Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent) recorded in the patient's medical file. | At the end of the study, an average of one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the timing of the vaccines (Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent) in relation to the date of initiation of anti-TNF alpha therapy | Number of patients who received a complete pneumococcal vaccination before initiation of treatment and the number of patients who received it after | At the end of the study, an average of one month | 
| Assessment of the number of injections prescribed and/or performed (Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent) for each patient | Number of patients who received an incomplete vaccination scheme (1 dose of Conjugated Pneumococcal Vaccine 13-valent or Unconjugated Pneumococcal Vaccine 23-valent). | At the end of the study, an average of one month | 
| Evaluation of the prescription or completion of the vaccination according to the characteristics of the patients and their comorbidities. | Analysis of the data to identify any significant differences according to the characteristics of the vaccinated and non-vaccinated patients (comorbidities, pathology for which the treatment was introduced .....). | At the end of the study, an average of one month | 
| Evaluation of the prescription or completion of the vaccination according to the medical specialty of the prescriber | Analysis of the data to identify any significant differences according to the medical specialty of the prescriber. | At the end of the study, an average of one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pneumococcal vaccine, Immunosupressed patients, Immunization status, Anti-TNF alpha